Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature.
capecitabine
chemotherapy
neuroendocrine tumor
neurofibromatosis type 1
somatostatin analogues
somatostatinoma
temozolomide
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
21 Aug 2020
21 Aug 2020
Historique:
received:
18
07
2020
revised:
11
08
2020
accepted:
17
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Somatostatinomas are rare neuroendocrine tumors (NET) that arise in the gastrointestinal (GI) tract. Because of their insidious growth, they are usually asymptomatic until late stages, presenting as malignant disease. We report the case of a 50-year-old woman who presented with epigastric abdominal pain, diarrhea and significant weight loss in the last two years. On clinical examination the patient met the criteria for neurofibromatosis type 1 (NF1). Abdominal CT and MRI revealed an infiltrative duodenal mass, with pancreatic invasion, locoregional enlarged lymph nodes and disseminated hepatic nodules. Microscopy and immunohistochemistry uncovered a neuroendocrine tumor, staining positive for chromogranin A (CgA), synaptophysin and somatostatin, with a Ki67 = 1%. Somatostatin receptors (SSTRs) type 2 were negative and SSTRs type 5 were positive in less than 50% of tumoral cells. Our patient was classified as a T3N1M1 stage IV metastatic duodenal grade 1 somatostatinoma and treatment with somatostatin analogues and chemotherapy with capecitabine and temozolomide was started, with so far abdominal imaging follow-up showing stable disease. When a patient is diagnosed with a rare NET, such as a somatostatinoma, it is of utmost importance to determine if it is a sporadic tumor or just a feature of a genetic disorder.
Identifiants
pubmed: 32825782
pii: diagnostics10090620
doi: 10.3390/diagnostics10090620
pmc: PMC7555390
pii:
doi:
Types de publication
Case Reports
Langues
eng
Subventions
Organisme : Universitatea de Medicină şi Farmacie "Carol Davila" Bucureşti
ID : Carol Davila University of Medicine and Pharmacy payed the APC
Références
Cancer Treat Rev. 2016 Mar;44:26-41
pubmed: 26855376
Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):807-17
pubmed: 16253902
Pathol Int. 2000 Feb;50(2):146-52
pubmed: 10792774
Eur J Endocrinol. 2005 May;152(5):757-67
pubmed: 15879362
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Int J Clin Exp Pathol. 2012;5(9):852-62
pubmed: 23119102
Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):507-17
pubmed: 16183524
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3
pubmed: 17122609
J Exp Clin Cancer Res. 1999 Mar;18(1):13-22
pubmed: 10374671
Arch Neurol. 1988 May;45(5):575-8
pubmed: 3128965
Cancer Sci. 2018 Jan;109(1):174-181
pubmed: 29055056
J Nucl Med. 2010 Jun;51(6):875-82
pubmed: 20484441
J Gastrointest Oncol. 2014 Aug;5(4):247-52
pubmed: 25083296
Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):439-49
pubmed: 20833335
Br Med J (Clin Res Ed). 1982 Dec 4;285(6355):1618-9
pubmed: 6128052
Cancer. 2011 Jan 15;117(2):268-75
pubmed: 20824724
J Surg Oncol. 1995 May;59(1):67-73
pubmed: 7745981
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
J Gastrointest Surg. 2010 Jun;14(6):1052-61
pubmed: 20300877
Neuroendocrinology. 2017;104(1):26-32
pubmed: 26731483
Arch Med Sci. 2016 Feb 1;12(1):1-9
pubmed: 26925113
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Acta Chir Scand Suppl. 1988;541:76-85
pubmed: 3291522
J Surg Oncol. 1987 Sep;36(1):8-16
pubmed: 3041116
Oncotarget. 2017 Oct 24;8(61):104046-104056
pubmed: 29262620
J Clin Oncol. 2008 Feb 20;26(6):963-70
pubmed: 18281671
Gut. 1998 Jun;42(6):792-4
pubmed: 9691916
Br J Cancer. 2015 Feb 3;112(3):523-31
pubmed: 25584486
Lancet Neurol. 2007 Apr;6(4):340-51
pubmed: 17362838
N Engl J Med. 2002 May 9;346(19):1486-8
pubmed: 12000821
Oman Med J. 2017 Sep;32(5):365-370
pubmed: 29026467
J Nucl Med. 2016 May;57(5):708-14
pubmed: 26769865
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 32294191
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
Acad Radiol. 2010 Mar;17(3):291-7
pubmed: 19962915
Cancers (Basel). 2020 Jan 14;12(1):
pubmed: 31947598
J Clin Oncol. 2004 Dec 1;22(23):4762-71
pubmed: 15570077
Korean J Intern Med. 2011 Mar;26(1):103-7
pubmed: 21437171
Dig Dis Sci. 1989 Mar;34(3 Suppl):14S-27S
pubmed: 2920654
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Minerva Endocrinol. 2004 Mar;29(1):19-24
pubmed: 15258554
Front Endocrinol (Lausanne). 2014 Feb 07;5:7
pubmed: 24570674
Surg Clin North Am. 2001 Jun;81(3):527-42
pubmed: 11459269
Endocr Relat Cancer. 2008 Mar;15(1):229-41
pubmed: 18310290
Surg Clin North Am. 1987 Apr;67(2):379-93
pubmed: 3031836
Endocr Pathol. 2009 Summer;20(2):92-100
pubmed: 19377845
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Genet Med. 2018 Jul;20(7):671-682
pubmed: 30006586
Pancreas. 2016 Nov;45(10):1386-1393
pubmed: 27622342
Eur J Nucl Med. 1993 Aug;20(8):716-31
pubmed: 8404961
Cancer. 2008 Sep 1;113(5):921-9
pubmed: 18618495
Neuroendocrinology. 2016;103(2):186-94
pubmed: 26731334
Indian J Pathol Microbiol. 2016 Jul-Sep;59(3):359-61
pubmed: 27510677
Cancer Biother Radiopharm. 2012 Nov;27(9):561-9
pubmed: 23078020
J Oncol. 2019 Feb 20;2019:9032753
pubmed: 30915122